Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

New drugs in development: What will be approved in 2025?

Q&A and live discussion

Date

17 Oct 2020

Session

New drugs in development: What will be approved in 2025?

Topics

Translational Research

Tumour Site

Presenters

Jordi Rodon

Authors

J. Rodon

Author affiliations

  • Early Drug Development, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

FGFR inhibitors

Presenter: Yohann Loriot

Session: New drugs in development: What will be approved in 2025?

Resources:

Slides

Webcast

Antibody Drug Conjugate (ADC)

Presenter: Victor Moreno Garcia

Session: New drugs in development: What will be approved in 2025?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.